Table 1.
Clinical characteristics of the study population for the selected clinical features.
|
Without Sepsis (n = 132) (mean, range) |
Sepsis (n = 106) (mean, range) |
|
|---|---|---|
| Maternal age (years) | 29 (15–49) | 27 (14–47) |
| Cervicovaginitis (%) | No 68 (51.5%) Yes 64 (48.5%) |
No 36 (34.95%) Yes 67 (65.05%) |
| Urinary tract infections (%) | No 54 (40.9%) Yes 78 (59.1%) |
No 35 (33.98%) Yes 68 (66.02%) |
| Premature rupture of membranes (%) | No 89 (67.4%) Yes 43 (32.6%) |
No 71 (68.93%) Yes 32 (31.07%) |
| Chorioamnionitis (%) | No 121 (91.7%) Yes 11 (8.3%) |
No 91 (88.35%) Yes 12 (11.65%) |
| Gender (%) | Male 68 (51.5%) Female 64 (48.5%) |
Male 53 (51.46%) Female 50 (48.54%) |
| Gestational age (weeks) | 33.49 (27.5–40.4) | 30.6 (25–40.4) |
| Weight (grams) | 1,842 (755–4,935) | 1,291 (520–3,605) |
| Fever (%) | No 115 (87.1%) Yes 17 (12.9%) |
No 72 (69.90%) Yes 31 (30.10%) |
| Hypothermia (%) | No 130 (98.5%) Yes 2 (1.5%) |
No 88 (85.44%) Yes 15 (14.56) |
| Tachycardia (%) | No 124 (93.9%) Yes 8 (6.1%) |
No 69 (69.99%) Yes 34 (33.01%) |
| Bradycardia (%) | No 130 (98.5%) Yes 2 (1.5%) |
No 101 (98.06%) Yes 2 (1.94%) |
| Tachypnea (%) | No 121 (91.7%) Yes 11 (8.3%) |
No 74 (71.84%) Yes 29 (28.16%) |
| Bradypnea (%) | No 115 (87.1%) Yes 17 (12.9%) |
No 103 (100.00%) Yes 0 (0%) |
| Apnea (%) | No 97 (73.5%) Yes 35 (26.5%) |
No 72 (69.90%) Yes 31 (30.10%) |
| Leukocytes (cells/mm3) | 12,631 (3,900–110,000) | 12,254 (2,300–33,200) |
| Neutrophils (cells/mm3) | 5,844 (876–39,058) | 7,239 (646–24,336) |
| Band cells (cells/mm3) | 248 (0–3,972) | 713 (40–3,240) |
| Band cells (%) | 2 (0–12) | 5 (0.02–20) |
| Relation band/neutrophils | 0.044 (0–0.250) | 0.12 (0.015–0.8) |
| Platelets (cells/mm3) | 275,013 (17,700–799,000) | 159,716 (242,000–593,000) |
| Catheter (%) | No 36 (27.3%) Yes 96 (72.7%) |
No 22 (21.36%) Yes 81 (78.64%) |
| Mechanical ventilation (%) | No 39 (29.5%) No invasive 79 (59.9%) Invasive 14 (10.6%) |
No 27 (26.21%) No invasive 59 (57.28%) Invasive 17 (16.51%) |
| Received initial pharmacological treatment (%) | No 65 (49.2%) Yes 67 (50.8%) |
No 1 (0.97%) Yes 102 (99.03%) |